Bioversys AG
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5
Ending by 2030
Jul 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 26, 2027The maintenance fee for Antibiotic Combination Therapies (US 11,766,425) comes due Mar 26, 2027. Unpaid by Sep 27, 2027, it lapses early.
- 1 fee due May 24, 2027The maintenance fee for Antimicrobial Compounds and Methods of Making and Using the Same (US 9,193,731) comes due May 24, 2027. Unpaid by Nov 24, 2027, it lapses early.
- 2 fees due Jun 5 to 29, 2027 · next Jun 5
- 1 fee due Aug 20, 2027The maintenance fee for Rifabutin treatment methods, uses, and compositions (US 11,903,934) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
- 1 fee due Oct 30, 2027The maintenance fee for Novel Compounds (US 11,969,423) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 23, 2026
- Oct 23 US 10,106,543 Antimicrobial Compounds and Methods of Making and Using the Same · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,912,329 | Composition for Treatment of Tuberculosis In force · High confidence | In force | High confidence | |
| US 9,193,731 | Antimicrobial Compounds and Methods of Making and Using the Same In force · High confidence | In force | High confidence | |
| US 9,221,827 | Antimicrobial Compounds and Methods of Making and Using the Same In force · High confidence | In force | High confidence | |
| US 11,999,739 | Antimicrobials Methods of Making and Using the Same In force · High confidence | In force | High confidence | |
| US 12,234,238 | Antimicrobial Compounds and Methods of Making and Using the Same In force · High confidence | In force | High confidence | |
| US 9,682,079 | Composition for treatment of pathogens that are resistant to tetracyclines In force · USPTO record | In force | USPTO record | |
| US 10,815,238 | Antimicrobial Compounds and Methods of Making and Using the Same In force · High confidence | In force | High confidence | |
| US 10,934,295 | Antimicrobials and Methods of Making and Using Same In force · High confidence | In force | High confidence | |
| US 11,253,499 | Novel Compounds In force · High confidence | In force | High confidence | |
| US 11,254,689 | Novel Compounds In force · High confidence | In force | High confidence |
Also on record, not counted in the 23: 3 patents in force now held by others · 13 lapsed for an unpaid fee · 2 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
8 pending · 4 abandoned · 3 no status recorded
Showing 1 to 10 of 15, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 19/292,217 | Aug 6, 2025 | No status recorded | |
| 19/181,189 | Purification of Rifabutin Formulations | Apr 16, 2025 | Pending |
| 19/088,662 | Rifabutin Treatment Methods, Uses, and Compositions | Mar 24, 2025 | Pending |
| 18/649,196 | Novel Compounds | Apr 29, 2024 | Abandoned |
| 18/876,551 | 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE Derivatives | Jun 26, 2023 | Pending |
| 18/875,383 | 8-HETEROCYCLIC-3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE Derivatives as Anti-Bacterials | Jun 26, 2023 | Pending |
| 18/855,839 | Rifabutin Analogs for the Treatment of Disease | Apr 6, 2023 | Pending |
| 18/833,285 | Rifamycin Derivatives for the Treatment of Diseases | Jan 27, 2023 | Pending |
| 18/722,156 | Rifabutin Analogs for the Treatment of Disease | Dec 21, 2022 | Pending |
| 17/978,647 | Antibiotic Combination Therapies | Nov 1, 2022 | Abandoned |
10 of 15 applications shown.
Pro members see all 15 published applications.